Cancer Family
Leukemia
CI-CAN-00000215Explore in graph →
HematologicTop-level1,766 active trials42 approved drugs708 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000215Explore in graph →
Clinical trials
8,441 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,353)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00003077 | Omega-3 Fatty Acids in Treating Patients With Advanced Cancer Who Have Significant Weight Loss | completed | Phase 1 / Phase 2 | 63 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jul 13, 2016 | clinicaltrials |
| NCT01436084 | SB1518 for Patients With Myelodysplastic Syndrome (MDS) | terminated | Phase 2 | 8 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 13, 2016 | clinicaltrials |
| NCT02046928 | Safety, Tolerability and Efficacy of A6 in Patients With Chronic Lymphocytic Leukemia (CLL) | terminated | Phase 2 | 5 | Ångstrom PharmaceuticalsINDUSTRY | 1 | Jul 13, 2016 | clinicaltrials |
| NCT02831192 | Microtransplantation in Older Patients With Acute Myeloid Leukemia | completed | Phase 2 | 150 | The Affiliated Hospital of the Chinese Academy of Military Medical SciencesOTHER | 1 | Jul 13, 2016 | clinicaltrials |
| NCT00003255 | Carboplatin Plus Topotecan in Treating Patients With Relapsed Acute Myelogenous Leukemia | completed | Phase 2 | 38 | Alliance for Clinical Trials in OncologyOTHER | 0 | Jul 12, 2016 | clinicaltrials |
| NCT00003700 | Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia | completed | Phase 2 | 163 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jul 6, 2016 | clinicaltrials |
| NCT00004857 | Fludarabine Followed by Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia | completed | Phase 2 | 86 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jul 6, 2016 | clinicaltrials |
| NCT00031980 | Cyclosporine in Treating Patients With Low Blood Counts Caused By Hematologic Cancer | completed | Phase 2 | 30 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jul 6, 2016 | clinicaltrials |
| NCT00002494 | Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma or Acute Lymphocytic Leukemia | completed | Phase 2 | 134 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jul 4, 2016 | clinicaltrials |
| NCT00053196 | Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer | completed | Phase 2 | 82 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jul 1, 2016 | clinicaltrials |
| NCT01297543 | Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Chemotherapy for Leukemia | completed | Phase 1 / Phase 2 | 45 | Cellerant TherapeuticsINDUSTRY | 1 | Jul 1, 2016 | clinicaltrials |
| NCT00002768 | Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Acute Myeloid Leukemia in Second Remission | completed | Phase 2 | 51 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jun 28, 2016 | clinicaltrials |
| NCT00811070 | Study Evaluating SKI-606 (Bosutinib) In Japanese Subjects With Philadelphia Chromosome Positive Leukemias | completed | Phase 2 | 63 | PfizerINDUSTRY | 1 | Jun 28, 2016 | clinicaltrials |
| NCT00492401 | Decitabine in Treating Patients With Previously Untreated Acute Myeloid Leukemia | completed | Phase 2 | 55 | National Cancer Institute (NCI)NIH | 1 | Jun 27, 2016 | clinicaltrials |
| NCT00578942 | Allo Non-myeloablative SCT Utilizing Matched Family Member Stem Cells Purged Using Campath | completed | Phase 2 | 48 | David Rizzieri, MDOTHER | 1 | Jun 24, 2016 | clinicaltrials |
| NCT01036009 | A Study of Withdrawal of Immunosuppression and Donor Lymphocyte Infusions Following Allogeneic Transplant for Pediatric Hematologic Malignancies | completed | Phase 2 | 43 | University of California, San FranciscoOTHER | 1 | Jun 23, 2016 | clinicaltrials |
| NCT02315118 | Pilot Study of Autologous T Lymphocytes With ADCC in Patients With CD20-Positive B-Cell Malignancies | unknown | Phase 1 / Phase 2 | 18 | National University Hospital, SingaporeOTHER | 1 | Jun 22, 2016 | clinicaltrials |
| NCT01218477 | Dasatinib Combination Therapy With the Smoothened (SMO) Inhibitor BMS-833923 in Chronic Myeloid Leukemia (CML) | completed | Phase 1 / Phase 2 | 33 | Bristol-Myers SquibbINDUSTRY | 7 | Jun 17, 2016 | clinicaltrials |
| NCT00751296 | Study of Lenalidomide in Previously Untreated, Symptomatic Chronic Lymphocytic Leukemia (CLL)(Rev-CLL) | terminated | Phase 2 | 27 | University Health Network, TorontoOTHER | 1 | Jun 16, 2016 | clinicaltrials |
| NCT01350947 | A Study of 5-Azacitidine (Vidaza®) in Patients With Chronic Myelomonocytic Leukemia | completed | Phase 2 | 11 | University of UtahOTHER | 1 | Jun 13, 2016 | clinicaltrials |
| NCT01658904 | Carfilzomib and Stem Cell Transplant for Plasma Cell Myeloma | terminated | Phase 1 / Phase 2 | 3 | National Cancer Institute (NCI)NIH | 1 | Jun 1, 2016 | clinicaltrials |
| NCT01703364 | Fludarabine/Rituximab Combined With Escalating Doses of Lenalidomide in Untreated CLL | completed | Phase 1 / Phase 2 | 12 | Arbeitsgemeinschaft medikamentoese TumortherapieOTHER | 1 | May 26, 2016 | clinicaltrials |
| NCT01088984 | Study of Bendamustine Hydrochloride for the Treatment of Pediatric Patients With Relapsed or Refractory Acute Leukemia | completed | Phase 1 / Phase 2 | 43 | Teva Branded Pharmaceutical Products R&D, Inc.INDUSTRY | 12 | May 23, 2016 | clinicaltrials |
| NCT00546377 | Pentostatin, Cyclophosphamide, Rituximab, and Mitoxantrone in Treating Patients With Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Cancer | completed | Phase 1 / Phase 2 | 50 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 12, 2016 | clinicaltrials |
| NCT01092741 | Late Chronic Phase Chronic Myelogenous Leukemia | completed | Phase 2 | 47 | M.D. Anderson Cancer CenterOTHER | 1 | May 11, 2016 | clinicaltrials |
| NCT01690065 | Nilotinib-Chemotherapy in CML Myeloid BP or Bcr-abl(+) AML(NICE-BORA) | unknown | Phase 2 | 46 | Ulsan University HospitalOTHER | 1 | May 11, 2016 | clinicaltrials |
| NCT02422719 | Radotinib as 3rd or Later Line Therapy in CP-CML(REVITAL) | unknown | Phase 2 | 73 | Ulsan University HospitalOTHER | 1 | May 11, 2016 | clinicaltrials |
| NCT01501708 | Caspofungin Based Combined Anti-fungal Therapy for Proven or Probable Invasive Fungal Infection | unknown | Phase 2 | 55 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | May 10, 2016 | clinicaltrials |
| NCT00427791 | Rituximab to the Preparative Regimen of Etoposide and Total Body Irradiation in Acute Lymphoblastic Leukemia | completed | Phase 2 | 23 | M.D. Anderson Cancer CenterOTHER | 1 | May 9, 2016 | clinicaltrials |
| NCT02029417 | Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia | terminated | Phase 2 | 2 | Roswell Park Cancer InstituteOTHER | 1 | May 9, 2016 | clinicaltrials |
| NCT01056614 | Fludarabine Phosphate, Busulfan, and Anti-Thymocyte Globulin Followed By Donor Peripheral Blood Stem Cell Transplant, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Malignancies | completed | Phase 2 | 23 | Fred Hutchinson Cancer CenterOTHER | 1 | May 6, 2016 | clinicaltrials |
| NCT01254890 | Sorafenib and 5-Azacitidine in Acute Leukemia + Myelodysplastic Syndrome | completed | Phase 1 / Phase 2 | 60 | M.D. Anderson Cancer CenterOTHER | 1 | May 6, 2016 | clinicaltrials |
| NCT00579111 | Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB) | terminated | Phase 1 / Phase 2 | 4 | Baylor College of MedicineOTHER | 1 | May 4, 2016 | clinicaltrials |
| NCT02533401 | A Study of Rituximab (MabThera) in Participants With Chronic Lymphocytic Leukemia (CLL) | completed | Phase 2 | 34 | Hoffmann-La RocheINDUSTRY | 2 | May 2, 2016 | clinicaltrials |
| NCT02337595 | Memory T-cell Infusion to Improve Immunity After TCR-alpha/Beta Depleted Hematopoietic Stem Cell Transplantation(45RA_NEG_DLI) | completed | Phase 1 / Phase 2 | 30 | Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyOTHER | 1 | Apr 22, 2016 | clinicaltrials |
| NCT00750659 | Nilotinib Pre and Post Allogeneic Stem Cell Transplantation | completed | Phase 2 | 24 | Sheba Medical CenterOTHER_GOV | 1 | Apr 20, 2016 | clinicaltrials |
| NCT01542944 | TevaGastrim for Stem Cell Mobilization Sibling Donors | completed | Phase 2 | 24 | Sheba Medical CenterOTHER_GOV | 1 | Apr 20, 2016 | clinicaltrials |
| NCT02507479 | Thiotepa-based Conditioning for Allogeneic Stem-cell Transplantation (SCT) in Lymphoid Malignancies | unknown | Phase 2 | 24 | Sheba Medical CenterOTHER_GOV | 1 | Apr 20, 2016 | clinicaltrials |
| NCT00510289 | Sorafenib in Myelodysplastic Syndrome | terminated | Phase 2 | 19 | Duke UniversityOTHER | 1 | Apr 19, 2016 | clinicaltrials |
| NCT00000603 | Cord Blood Stem Cell Transplantation Study (COBLT) | completed | Phase 2 | — | National Heart, Lung, and Blood Institute (NHLBI)NIH | 0 | Apr 14, 2016 | clinicaltrials |
| NCT00623935 | Blood Stem Cell Transplantation for the Treatment of Older Patients With Acute Myelogenous Leukemia | completed | Phase 2 | 56 | University of Michigan Rogel Cancer CenterOTHER | 1 | Apr 8, 2016 | clinicaltrials |
| NCT00532129 | A Study of MabThera (Rituximab) Plus Chlorambucil in Participants With Chronic Lymphocytic Leukemia. | completed | Phase 2 | 100 | Hoffmann-La RocheINDUSTRY | 1 | Apr 6, 2016 | clinicaltrials |
| NCT00615589 | Stem Cell Transplantation To Treat High Risk Multiple Myeloma With Reduced Toxicity Myeloablative Conditioning Regimen | terminated | Phase 2 | 22 | University of Michigan Rogel Cancer CenterOTHER | 1 | Apr 4, 2016 | clinicaltrials |
| NCT01573247 | Safety Study of AKN-028 in Patients With Acute Myelogenous Leukemia | terminated | Phase 1 / Phase 2 | 25 | Akinion Pharmaceuticals ABINDUSTRY | 4 | Mar 25, 2016 | clinicaltrials |
| NCT00529360 | Allogeneic Stem Cell Transplant With Clofarabine, Ara-C and TBI for AML and ALL | completed | Phase 1 / Phase 2 | 32 | New York Medical CollegeOTHER | 1 | Mar 24, 2016 | clinicaltrials |
| NCT01518153 | Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT) | terminated | Phase 2 | 16 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 17, 2016 | clinicaltrials |
| NCT01301820 | Elderly Patients With Acute Myeloid Leukemia (AML), Maintenance Phase After Complete Remission (CR) | completed | Phase 2 | 120 | French Innovative Leukemia OrganisationOTHER | 1 | Mar 16, 2016 | clinicaltrials |
| NCT01019317 | Fludarabine and Cytarabine in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS) | completed | Phase 2 | 151 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 15, 2016 | clinicaltrials |
| NCT01461538 | Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies | completed | Phase 2 | 84 | Seagen Inc.INDUSTRY | 1 | Mar 4, 2016 | clinicaltrials |
| NCT00850382 | Dasatinib (Sprycel™) in Patients With Newly Diagnosed Core Binding Factor (CBF) Acute Myeloid Leukemia (AML) | completed | Phase 1 / Phase 2 | 89 | University of UlmOTHER | 2 | Mar 1, 2016 | clinicaltrials |
Data updated 24 days agoSource updated Jul 13, 2016source: clinicaltrials